Introduction:
In Yash Charitable Trust and Others v. Union of India and Others (W.P.(C) No. 369/2022), the Supreme Court of India delivered a significant judgment addressing the legality and ethicality of administering stem cell therapy as a treatment for Autism Spectrum Disorder (ASD). The petitioners included Yash Charitable Trust, a Mumbai-based non-governmental organization, Dr. Vibha Krishnamurthy, a developmental pediatrician, the Forum for Medical Ethics Society represented by Dr. Sanjay Nagral, and KS Ganpathy, a parent whose child had undergone stem cell therapy for autism. The petition was filed against the Union of India, the Ministry of Health and Family Welfare, the National Medical Commission (NMC), and the Indian Council of Medical Research (ICMR).
The petitioners sought intervention from the Court against the growing trend of clinics across India offering stem cell therapy as a cure or treatment for autism, alleging that such therapies were untested, unproven, and commercially exploitative. The case required the Court to evaluate whether medical practitioners could legally offer stem cell therapy as routine treatment for ASD and whether existing statutory frameworks under the Drugs Act, 1940 and the New Drugs and Clinical Trials Rules, 2019 adequately regulate stem cell research and therapy. The bench comprising Justice J.B. Pardiwala and Justice R. Mahadevan examined these concerns in detail and delivered a landmark judgment that has far-reaching implications for medical ethics, patient rights, and regulatory accountability in India.
Arguments of the Petitioners:
The petitioners contended that stem cell therapy was being aggressively promoted by several medical institutions and clinics as a cure or effective treatment for autism despite the absence of credible scientific evidence supporting such claims. They submitted that Autism Spectrum Disorder is a complex neurodevelopmental condition characterized by impairments in communication, social interaction, and repetitive behavioural patterns. While therapies such as occupational therapy, speech therapy, and behavioural therapy have demonstrated benefits in improving the quality of life of individuals with autism, there is currently no recognized medical cure for the disorder.
The petitioners argued that the widespread commercialization of stem cell therapy was exploiting vulnerable families who were emotionally distressed and financially burdened while searching for potential treatments for their children. They emphasized that clinics often charged exorbitant amounts for such therapies, creating a profit-driven medical practice that disregarded patient safety and scientific integrity.
The petitioners relied heavily on the New Drugs and Clinical Trials Rules, 2019, framed under the Drugs and Cosmetics Act, 1940. They submitted that stem cell therapy falls within the ambit of “new drugs” and therefore must undergo rigorous clinical trials and regulatory approval before being offered to patients. According to the petitioners, stem cell therapy for ASD had not undergone such mandatory trials and therefore its routine clinical use was unlawful.
The petitioners further cited the recommendations of the Ethics and Medical Registration Board (EMRB) of the National Medical Commission dated December 6, 2022, which clearly stated that stem cell therapy is not recommended for the treatment of autism. They also referred to the National Guidelines for Stem Cell Research (NGSCR), 2017, and the National Ethical Guidelines issued by ICMR, which restrict the use of stem cells to approved clinical trials conducted under strict regulatory supervision.
Another important contention raised by the petitioners was that the consent obtained from patients or their guardians for undergoing stem cell therapy was not valid because such consent was based on incomplete or misleading information. They argued that families were often made to believe that stem cell therapy offered a legitimate chance of curing autism, which created a therapeutic misconception and undermined the principle of informed consent. The petitioners therefore sought strict enforcement of existing laws to prevent unethical medical practices and to safeguard public health.
Arguments of the Respondents:
The respondents, including the Union Government and regulatory medical bodies, acknowledged the complexities surrounding stem cell therapy but highlighted the evolving nature of scientific research in regenerative medicine. They submitted that stem cell research holds significant potential for future medical breakthroughs and therefore should not be completely prohibited.
The respondents argued that certain types of stem cells, particularly autologous stem cells derived from the patient’s own body, do not always qualify as “new drugs” under the New Drugs and Clinical Trials Rules, 2019, especially when they are subjected to minimal manipulation. They contended that in such cases, the regulatory requirements applicable to new drugs might not strictly apply.
The government authorities also emphasized that India already has a comprehensive regulatory framework governing stem cell research through the Drugs Act, 1940, the NDCT Rules, 2019, the National Ethical Guidelines, and the NGSCR, 2017. According to them, these guidelines ensure ethical compliance and scientific scrutiny of stem cell-based treatments.
The respondents further argued that patients and their families often voluntarily choose stem cell therapy as a last resort after exploring conventional treatment options. They suggested that patient autonomy should be respected and individuals should have the freedom to opt for experimental treatments, particularly when conventional therapies fail to provide desired outcomes.
However, the respondents acknowledged the need for strict monitoring of clinics offering stem cell therapy and expressed willingness to strengthen regulatory oversight. They also assured the Court that steps were being taken to clarify legal ambiguities and to ensure that stem cell therapies are administered only in accordance with approved scientific protocols.
Court’s Judgment:
The Supreme Court delivered a comprehensive judgment addressing both legal and ethical aspects of stem cell therapy for autism. The Court framed two primary issues for determination: whether medical practitioners are legally permitted to offer stem cell therapy as routine clinical treatment for ASD, and whether the Drugs Act, 1940 and NDCT Rules, 2019 provide an adequate regulatory framework for stem cell research.
Legality of Offering Stem Cell Therapy as Routine Treatment
The Court examined the recommendations issued by the Ethics and Medical Registration Board of the National Medical Commission, the National Guidelines for Stem Cell Research, and the National Ethical Guidelines formulated by ICMR. It observed that these regulatory instruments uniformly state that stem cell therapy is not recognized as an established or scientifically validated treatment for autism.
The Court categorically held that offering stem cell therapy as a routine clinical service for ASD amounts to medical malpractice. It emphasized that medical practitioners are bound by the “standard of care” principle, which requires them to provide treatments supported by scientific evidence and accepted medical practice. Administering unproven therapies outside approved clinical trials violates this standard and exposes patients to unnecessary risks.
The Court further observed that stem cell therapy can only be used within the framework of monitored clinical research trials conducted with the objective of advancing scientific knowledge. Any use of stem cells outside such clinical trials is unethical and legally impermissible.
Patient Autonomy and Valid Consent
The Court also addressed the argument that patient autonomy allows individuals to consent to experimental treatments. It held that consent is valid only when it is based on adequate and accurate information. The Court relied on its earlier decision in Samira Kohli v. Dr. Prabha Manchanda, which emphasized the importance of informed consent in medical practice.
The Court found that stem cell therapy for autism does not meet the requirements of informed consent because reliable information regarding its safety and efficacy is not available. Patients and their families often suffer from therapeutic misconception and falsely believe that the therapy offers guaranteed results. The Court held that continuing treatment under such misconceptions constitutes a gross violation of medical ethics.
Regulatory Framework under Drugs Act and NDCT Rules
The Court held that stem cells fall within the definition of “drugs” under Section 3(b)(i) of the Drugs Act, 1940, as they qualify as substances intended for use in treatment. It observed that even if certain stem cell therapies do not qualify as “new drugs” under the NDCT Rules, they remain subject to regulatory oversight under the broader framework governing biomedical and health research.
The Court explained that Chapter IV of the NDCT Rules, 2019 provides a detailed regulatory mechanism for stem cell research. Rules 15 and 16(4) make compliance with the National Ethical Guidelines legally binding. Clause 7.9.1 of these guidelines mandates that all stem cell research involving human participants must be conducted as clinical trials, except for specific hematological applications such as bone marrow transplantation.
The Court further clarified that research involving minimally manipulated stem cells must still comply with the regulatory framework applicable to biomedical research and must be conducted under strict ethical supervision.
Directions Issued by the Court:
The Court directed that stem cell therapy for autism cannot be offered as a commercial or routine clinical service. It urged the Union Government to consolidate and clarify existing legal provisions to prevent misuse of stem cell therapy and to ensure uniform enforcement across the country.
The Court also addressed the concerns of patients who were already undergoing stem cell therapy. It directed the Ministry of Health and Family Welfare, in consultation with AIIMS and the National Medical Commission, to devise a mechanism to ensure that such patients can continue receiving appropriate medical support until they are transitioned to institutions conducting approved clinical trials. The Court granted four weeks for implementing these directions.
The judgment emphasized the need to balance scientific innovation with patient safety and ethical medical practice. It underscored that the advancement of medical science must not come at the cost of vulnerable patients who are often subjected to experimental treatments without adequate safeguards.